Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 52

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 8
Chunk 52
---
 regulatory and compliance obligations, the competitive landscape,
and our ability to enter into strategic partnerships or other collaborative arrangements. We expect to continue to incur increasing negative
cash flows and net losses for the foreseeable future.

Cash Flows

Cash flows from operating, investing and financing
activities, as reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows:

    (In thousands) For the three months ended 

    June 30,  2025  
    June 30,  2024 
  
    Cash (used in) provided by: 

    Operating activities 
    $(1,715) 
    $(1,748)
  
    Investing activities 
     –  
     – 
  
    Financing activities 
     (5) 
     5,379 
  
    Effect of exchange rate changes on cash 
     (15) 
     (1)
  
    Net decrease in cash and restricted cash 
    $(1,735) 
    $(3,630)

NET CASH USED IN OPERATING ACTIVITIES. Net cash used
in operating activities was approximately $1,715,000 for the three months ended June 30, 2025, compared to approximately $1,748,000 for
the same period in 2024. The decrease was primarily driven by a lower net loss in the current period. However, this improvement was largely
offset by unfavorable changes in working capital, including decreases of approximately $393,000 in amounts due to related parties and
$461,268 in accounts payable and other current liabilities. These were partially offset by modest increases in non-cash charges and favorable
changes in prepaid expenses and other current assets.

NET CASH USED IN INVESTING ACTIVITIES. We did not
use cash for investing activities in the three months ended June 30, 2025 and June 30, 2024.

 21 

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES.
Net cash provided by financing activities decreased by approximately $5.4 million for the three months ended June 30, 2025. In the current
period, financing activity was limited to approximately $5,000 used for tax withholding related to the settlement of restricted stock
units. By contrast, in the same period of the prior year, we raised approximately $5,379,000, net of placement agent fees and offering
costs, through the sale and issuance of common